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Transferrina transferrin homologue that binds iron (Fe) through a high afﬁnity Fe-binding
site. MTf has been implicated in diverse processes, e.g., iron metabolism, plasminogen activation, eosinophil
differentiation and cancer cell migration, proliferation and tumourigenesis. Our previous studies using a
knockout mouse demonstrated that MTf does not have an essential function in Fe metabolism (E.O. Sekyere,
L.L. Dunn, Y.S. Rahmanto, D.R. Richardson, Role of melanotransferrin in iron metabolism: studies using
targeted gene disruption in vivo, Blood 107 (2006) 2599–2601). However, it does play a role in melanoma
cell proliferation and tumourigenesis. In this investigation, we report generation and characterization of
transgenic mice bearing the MTf gene (MTfTg) produced via lentiviral delivery. In MTfTg mice, MTf mRNA and
protein were hyper-expressed in tissues compared to control mice. These animals exhibited no gross
morphological, histological, nor Fe status changes. TheMTfTg mice were also born in accordance with classical
Mendelian ratios. However, hyper-expression of MTf leads to a mild, but signiﬁcant decrease in erythrocyte
count. This animal provides a novel MTf hyper-expression transgenic model for further investigating the
biological function(s) of MTf.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
Melanoma is a malignant tumour of melanocytes that underlies
the majority of skin cancer-related deaths. Approximately 160,000
new cases of melanoma are diagnosed every year worldwide with an
increased frequency in white populations living in sunny climates [1].
Melanotransferrin (MTf), or human melanoma-associated antigen
p97, was one of the ﬁrst cell surface markers associated with
melanoma [2]. It was also described as an oncofetal antigen expressed
in large amounts in neoplastic cells (particularly malignant melanoma
cells) and fetal tissues [3]. Melanotransferrin has also been identiﬁed
in normal tissues, including sweat gland ducts [4], avian eosinophils
[5], porcine fetal intestinal epithelial cells [6], liver endothelial cells
[7], rabbit and mouse cartilage [8], avian proximal kidney tubules [5]
and the normal endothelium and reactive microglia of the brains of
Alzheimer's disease patients [9]. Nonetheless, the highest levels of
MTf are associated with melanoma cells [10,11].
Melanotransferrin is a membrane-bound protein attached by a
glycosyl phosphatidylinositol (GPI) anchor. It is a homologue of the
iron (Fe)-binding and transport proteins, transferrin (Tf), ovotrans-
ferrin and lactoferrin, having 37–39% sequence homology [12–14].
MTf shares many important characteristics with serum Tf, including+61 2 9351 3429.
. Richardson).
ll rights reserved.co-localization on chromosome 3, similar disulﬁde bonds and an
identical N-terminal Fe-binding site [10,12,15]. Importantly, isolated
and puriﬁed MTf has the ability to bind Fe from Fe(III) citrate
complexes, suggesting a possible role for MTf in Fe transport [10,15].
Despite these similarities, an obvious difference between MTf and
serum Tf is that the latter is free in the plasma, while MTf is mainly
found bound to the cell membrane [14,16,17].
Due to its high homology with Tf, its ability to bind Fe and its high
expression on melanoma cells, MTf was initially hypothesized to play a
role in the Fe metabolism of tumour cells [10,14]. However, recent
phenotypic characterization of the MTf knockout (MTf−/−) mouse
indicated that MTf does not play an essential role in Fe metabolism nor
homeostasis [14,18,19]. Indeed,microarrayanalysis examining theMTf−/−
mouse did not identify any signiﬁcant changes in the expression of
molecules that play an appreciable role in Fe metabolism [18]. These
recent ﬁndings were supported by previous studies in our laboratory that
demonstrated neither the membrane-bound or soluble forms of MTf
efﬁciently donate Fe to SK-Mel-28 melanoma cells, nor bind to either
transferrin receptor 1 or 2 (TfR1 or TfR2) [20–23]. Nonetheless, the ability
of MTf to bind Fe remains the only well characterized function of the
protein [15].
It has been suggested that MTf may function in a range of
physiological and pathological processes such as Fe transport across
the blood–brain barrier, melanoma cell proliferation/invasiveness/
tumourigenicity, Alzheimer's disease, eosinophil differentiation,
chondrogenesis and arthritis [5,8,18,24–28]. More recently, it has
Fig. 1. (A) Schematic illustration of the melanotransferrin (MTf) lentiviral transgene. The transgene incorporates lentiviral elements (i.e., 5′- and 3′-long-terminal repeats [LTR], psi
sequence, rev responsive element [RRE], central termination sequence/polypurine tract [cts/pput], internal ribosome entry site [IRES] and woodchuck hepatitis post-transcriptional
regulatory element [WPRE]), the human ubiquitin-c promoter, the coding sequence (CDS) of mouseMTf and the lacZ reporter gene. The position of the lenti-probe for the veriﬁcation
of the transgene on the genomic levels using Southern blot is indicated. (B) Veriﬁcation of the transgene in genomic DNA. Genomic DNA digested with EcoRV, from the tail tip of 76
potential founder mice were used for Southern blot analysis to determine the presence of the MTf transgenic cassette. The lenti-probe, used in Southern blot analysis, recognized a
single 1.9-kb fragment of the expected size. Tenmice (# 2, 7, 22, 32, 35, 36, 39, 42, 43 and 59) were positively identiﬁed asMTf transgenic mice (MTfTg). (C–D)MTf hyper-expression in
the mouse at the mRNA and protein levels. (C) RT-PCR and densitometric analysis of MTf and transferrin receptor 1 (TfR1) mRNA transcripts in the brain, heart, kidney, liver, spleen,
testis and bone marrow from theMTfTg andMTfWTmice. (D) Western and densitometric analysis of MTf and TfR1 in the heart, kidney, liver, spleen, testis and bone marrow from the
MTfTg and MTfWT mice. Results are representative of 3 experiments. Results are mean±standard deviation (SD).
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angiogenesis, cell migration/invasion and plasminogen activation
[29–31]. However, the exact biological function of MTf remains
unclear and difﬁcult to determine. In fact, generation and extensive
examination of theMTf knockout (MTf−/−) mousemodel provided no
evidence for the role of MTf in Fe metabolism nor homeostasis [18,19].
Hence, further investigation into the function of MTf is vital.
To assist in determining the biological role of MTf, we implemen-
ted whole genome microarray analysis using the MTf−/− mouse and
four in vitromodels of MTf down- and up-regulation across a range of
cell lines [18,19,28]. In these latter studies, we identiﬁed a number of
common changes in gene expression across all ﬁve models. The most
important of these were ATP-binding cassette sub-family B member 5
(Abcb5), transcription factor 4 (Tcf4) and thiamine triphosphatase
(Thtpa) which were modulated by MTf expression [28]. The products
of these three genes are involved in membrane transport/cell fusion
[32], cell proliferation/survival [33–35] and energy metabolism [36],
respectively. Moreover, in the cell line models, we observed that MTf
hyper-expression leads to increased cellular proliferation, while MTf
down-regulation resulted in decreased proliferation [18,28]. These
results suggested that MTf may have direct or indirect roles in
modulating growth.
To further elucidate MTf function, the current investigation
generated and characterized transgenic mice bearing the MTf gene
under the control of an ubiquitin-c promoter. Clearly, this approach
complemented our previous studies on the MTf−/− mice to provide
complete understanding of the possible role(s) of MTf in vivo [18,19].
In this investigation, the transgenic mice hyper-expressed MTf (MTfTg)
in a variety of tissues and showed a mild haematological phenotype
consisting of decreased erythrocyte number in the peripheral blood.
This study has generated the ﬁrst MTfTg mouse model for examining
the function of MTf in vivo.
2. Materials and methods
2.1. Animals
All procedures in animal experiments were approved by the
University of Sydney Animal Ethics Committee. All mice were housed
under a 12 h light–dark cycle, fed routinely with basal rodent chow
(0.02% Fe) and watered ad libitum.
2.2. Plasmid construction and generation of MTfTg transgenic mice
The generation of MTfTg transgenic mice was performed by
standard procedures using a lentiviral gene delivery system [37,38].
This method was chosen as lentiviruses display two important
advantages, including: (i) the ability to infect non-cycling and post-
mitotic cells; and (ii) lentiviral vectors are not developmentally
silenced [37,39,40]. Brieﬂy, a 2247-bp fragment containing the mouse
MTf coding sequence (CDS) was generated with 5′- and 3′-SalI
restriction endonuclease sites using PCR. The fragment was cloned
downstream of the human ubiquitin-c promoter (UbiC) in the vector
pPCR to generate pPCR-MTf (Fig. 1A). A 3492-bp XbaI fragment,
encompassing the UbiC promoter [38] and the mouse MTf CDS wereTable 1
Primers for genotyping and ampliﬁcation of mouse mRNA.
Pair no. Primer name Genotype/accession no. Oligonucleotides (5′–3′)
Forward
1 MTfTg NM_013900 ACGACCATAACAAGAACGG
2 MTfWT # ACGACCATAACAAGAACGG
3 mMTf NM_013900 AGGCTCCTGAGCGTGACTT
4 mβ-actin NM_007393 CCCGCCACCAGTTCGCCATGG
#Genotyping primers for MTfWT were designed against the mouse genome (database versi
were predicted using UCSC In-Silico PCR software [51].inserted into a pTZV3 lentiviral gene-transfer cassette (Fig. 1A).
Flanking sequences at the 5′ and 3′ ends consisted of HIV long-
terminal repeat (LTR) sequences which are required for integration of
the vector into the genome (Fig. 1A) [40]. The Woodchuck hepatitis
virus post-transcriptional regulatory element was used in the vector
to increase the levels of transcription (Fig.1A) [41]. A psi sequencewas
located at the 3′ end of the HIV LTR and is necessary for packaging viral
RNA into viral capsids. For the translation of the lacZ reporter gene, an
internal ribosome entry site (IRES) sequence was used instead of an
internal promoter to avoid the potential of suppression [42]. The
lentiviral construct was used for pronuclear injection into single cell
mouse embryos to ensure genomic integration [37].
Founders were identiﬁed by Southern blot analysis. Brieﬂy,
genomic DNA digested with EcoRV, from the tail tip of potential
founder mice were used for Southern blot analysis to determine the
presence of the MTf transgenic cassette. The lenti-probe, used in
Southern blot analysis, recognized a single 1.9-kb fragment of the
expected size that represents the presence of the lentiviral transgene
(Fig. 1A). A female founder with the highest expression of MTf and
consistent transmission was obtained. Transgenic animals were
backcrossed onto a C57/BL6J background for 3 generations and a
MTfTg line from the founder (founder #43) was achieved. A second
MTfTg line was also established from a male founder (founder #2) that
showed considerable MTf expression and consistent transmission.
All phenotypic characterization of the MTfTg animals was carried
out using heterozygous mice that were littermates. This was done for
two reasons: (1) to avoid the possibility of an aberrant phenotype due
to gene inactivation in homozygous mice induced by the insertion of
the MTf-containing lentiviral construct into the genome, and (2)
because the hyper-expression of MTf was already pronounced inMTfTg
heterozygous mice (see Results and Fig. 1C and D).
2.3. Veriﬁcation of the MTf transgene at the genomic, mRNA and protein
level
Genomic DNA from mice was prepared from tail tips using
standard methods [19]. Genotyping was carried out by PCR using
Taq DNA polymerase (Invitrogen, Melbourne, Victoria, Australia)
using the primers in Table 1. Total RNA was isolated by homogenizing
tissues in 1 mL of TRIzol® reagent (Invitrogen) as described previously
[18]. Semi-quantitative RT-PCR was performed by standard proce-
dures [18] using the primers in Table 1. As an internal control, β-actin
was ampliﬁed from the same samples. Identities of transcripts were
conﬁrmed by DNA sequencing [43]. Protein isolation and Western
analysis were performed using established techniques [44]. A
polyclonal antibody generated by our laboratory was used to detect
mouseMTf [19]. The TfR1 antibodywas from Zymed Laboratories (San
Francisco, CA). β-actin expression was assessed as a loading control
and the antibody was from Sigma (clone AC-15).
2.4. Determination of haematological and serum chemistry indices
Blood samples were collected from the hearts of anesthetized mice
by cardiac puncture. Serum chemistry and haematological parameters
were determined using a Konelab 20i analyser (Thermo-ElectronProduct
size (bp)Priming sites Reverse Priming sites
2069–2087 GAGAACGCGAGGAAGGAG 2314–2331 263
# GAGAACGCGAGGAAGGAG # 777
121–139 CACTGTGCTGTGCTTCAGG 795–813 693
64–84 AAGGTCTCAAACATGATCTGGGTC 437–460 397
on February 2006; http://genome.ucsc.edu/). Primer annealing sites and product size
Table 2
Offspring from multiple matings.
Parents
genotype
No. of pups Total no.
of litters
Average
litter size
(mean±SD)
Deaths/litter
(mean±SD)Male Female Total Total
deaths
Tg×Tg 58a 53b 111 38 24 4.6±2.4 1.6±1.4
Tg×WT 120c 108d 228 16 39 5.8±2.4 0.4±0.7
WT×WT 44 39 83 4 14 5.9±2.7 0.3±0.6
Pups were separated from the parents after weaning.
a Male offspring from Tg×Tg breeding pairs consisted of 34 MTfTg and 24 MTfWT.
b Female offspring from Tg×Tg breeding pairs consisted of 38 MTfTg and 15 MTfWT.
c Male offspring from Tg×WT breeding pairs consisted of 56 MTfTg and 64 MTfWT.
d Female offspring from Tg×WT breeding pairs consisted of 58 MTfTg and 50 MTfWT.
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Medical Electronics Co., Kobe, Japan), respectively.
2.5. Histopathological analysis
Blood smears were prepared and stained with Giemsa. A variety of
organs were dissected, ﬁxed in 10% formalin, sectioned and stained
with hematoxylin and eosin and Perls' stain (to determine Fe-loading)
for microscopic examination. These slides were assessed by an
independent veterinary pathologist (Rothwell Consulting Pty Ltd,
Sydney, Australia).
2.6. Total tissue Fe, copper and zinc determinations
Total tissue Fe, copper (Cu) and zinc (Zn) concentrations were
measured using inductively coupled plasma atomic emission spectro-
metry (ICP-AES) via standard techniques [45].
2.7. Statistical analysis
Results are expressed as either the mean±standard error of the
mean (SEM) or mean±standard deviation (SD). Student's t-test
was used to assess differences between MTf wild-type (MTfWT) and
MTfTg mice. Data were considered statistically signiﬁcant when
pb0.05.
3. Results
Our previous studies established a MTf−/− mouse model that did
not show any signiﬁcant phenotypic abnormalities, indicating that
MTf does not play an essential role in Fe metabolism [18,19]. However,
the possibility that hyper-expression of MTf in vivo could lead to some
distinct phenotypic abnormalities (e.g., alterations in Fe metabolism)
has not been explored. This was considered important to assess as
disease states (e.g., melanoma and Alzheimer's disease) have been
associated with high MTf expression [3,11,46]. Moreover, forced
hyper-expression of MTf in Chinese hamster ovary (CHO) cells leads
to increased Fe uptake from Fe-citrate [16]. Hence, there was the
possibility that changes in Fe homeostasis and other abnormalities
could occur in MTfTg mice hyper-expressing MTf.
To examine the effect of MTf hyper-expression in vivo, MTfTg mice
were generated and thorough phenotypic assessment of the mor-
phology, histology, haematology and biochemistry of the MTfTg
animals were performed.
3.1. Generation of MTfTg mice
To generate a mouse with high MTf expression, we used a
lentiviral MTf expression vector (Fig. 1A) [37,38]. Genomic insertion
of the mouse MTf transgene was initially conﬁrmed by using
Southern blot hybridisation on DNA isolated from the tail tips of
mouse pups (Fig. 1B). The blot was probed with the “lenti-probe”
that was speciﬁc to the lentiviral sequences inserted along with the
MTf transgene (Fig. 1A). Using a combination of the EcoRV
restriction digest and Southern blot analysis, a 1.9-kb band was
observed in the MTfTg mice, but not in animals without lentiviral
insertion (Fig. 1B). These results indicated that insertion of the
lentiviral gene-transfer cassette containing the MTf transgene was
successful.
Seventy-six potential transgenic founders were screened for the
presence of the transgenic construct. Ten founders were identiﬁed
which contained the lentiviral transgene (Fig. 1B).
Genotyping of the MTfTg mouse was determined using standard
PCR analysis on the DNA isolated from the pups. PCR was performed
using primer pairs 1 and 2 (Table 1) for MTfTg and MTfWT animals,
respectively. The two pairs consist of the same forward and reverseprimers that anneal on exons-15 and -16, respectively, of the mouse
MTf gene. Hence, MTfTg mice, with MTf cDNA insertion, will have
both 263-bp and 777-bp bands, while MTfWT animals have only a
777-bp band.
3.2. Assessment of MTf transgene hyper-expression at the mRNA and
protein levels
To conﬁrm that lentiviral insertion resulted in hyper-expression of
MTf, RT-PCR analysis was performed (Fig. 1C). Primers speciﬁc for
exons-1 and -6 were used to amplify across the region of MTf and to
generate a 693-bp product. The RT-PCR product was detected in
various organs, such as the brain, heart, kidney, liver, spleen and testis,
from both MTfTg and MTfWT animals (Fig. 1C). Indeed, the highest
expression ofMTfmRNAwas observed in the brain, heart, kidney and
testis of MTfWT animals (Fig. 1C). MTf mRNA expression in MTfTg mice
was signiﬁcantly (pb0.0001) hyper-expressed by 4- to 30-fold
compared to the MTfWT littermates in all organs examined over 3
experiments (Fig. 1C).
As a measure of Fe status, expression of TfR1 mRNA was assessed
which is regulated by the intracellular levels of this metal [47]. The
expression of TfR1 mRNA and protein was compared between the
genotypes and found to be very similar (Fig. 1C and D). Hence, hyper-
expression ofMTf does not affect Fe pools that control TfR1 expression.
Direct tissue Fe measurements also demonstrated no signiﬁcant
alteration between MTfTg and MTfWT mice (see below). These results
were in good agreement with studies assessing the MTf−/− mouse,
where deletion of MTf resulted in no alteration in TfR1 mRNA nor
protein expression [19].
Western analysis was carried out to determine whether MTf
protein was also hyper-expressed in MTfTg mice as a result of the
lentiviral modiﬁcation (Fig. 1D). A signiﬁcant (pb0.01) 6- to 42-fold
increase of the 82-kDa MTf protein was detected in the MTfTg heart,
kidney, liver, spleen and testis relative to the MTfWT animals over 3
experiments (Fig. 1D). Examination of MTf mRNA and protein
expression in the bone marrow (Fig. 1C and D) and also full blood
(data not shown) demonstrated hyper-expression to a similar extent
as that found in other tissues shown.
A previous study by others [27] and work by our laboratory [18]
noted that MTf was found at 82-kDa rather than 97-kDa using SDS-
PAGE gels [2]. These data further conﬁrmed the wide distribution of
MTf hyper-expression amongst tissues in the MTfTg animals. As found
for TfR1 mRNA levels, examination of TfR1 protein expression did not
show any signiﬁcant difference between the genotypes (Fig. 1D).
3.3. Analysis of reproductive capabilities of MTfTg mice
Testes have been shown to have relatively high levels ofMTfmRNA
expression inMTfWT mice [19,43], this potentially suggested a role for
MTf in reproduction. In order to determine whether fertility was
affected in the MTfTg mice, multiple matings were carried out. Each
pair of MTfTg×MTfTg, MTfTg×MTfWT and MTfWT×MTfWT mice were
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separated from the parent after weaning. Physical observation of the
MTfTg andMTfWT pups indicated no signiﬁcant (pN0.05) differences in
the phenotypes between these animals. The calculated number of
deaths/litter showed a non-signiﬁcant (pN0.05) trend that was four-
fold higher in the MTfTg×MTfTg pair compared to the MTfTg×MTfWT
andMTfWT×MTfWT pairs (Table 2). The average number of pups born/
litter showed no signiﬁcant (pN0.05) difference between the three
mating combinations (Table 2). This suggested that hyper-expression
of mouse MTf did not affect fertility. Growth and reproductive
capability were important to assess in this in vivo model as studies
in vitro demonstrated a role for MTf in proliferation [18,28–30].
3.4. Offspring analysis from heterozygous breeding pairs
Mice that were heterozygous for MTf hyper-expression were
interbred against their MTfWT littermates to generate litters that
consisted ofMTfTg andMTfWTgenotypes as determined by PCR analysis
of tail tip DNA. Overall, from 228 pups born, 114 were MTfTg and 114
were MTfWT (Table 2). This clearly conforms to the predicted
Mendelian ratios of 1:1, expected from the MTfTg×MTfWT breedingFig. 2. Post-natal growth rate and relative organ weights of theMTfTg andMTfWTmice. (A–B)
of male (A) and female (B) MTfTg and MTfWT mice were measured weekly starting at the ag
weight or growth rates between either male or femaleMTfTg and MTfWT littermates (n=8/g
and female (D)MTfTg andMTfWT littermates at autopsy. No differences were observed in the
liver, spleen and testis from either male or female MTfTg and MTfWT mice (n=8/group). Repair. TheMTfTg pups that had hyper-expression of mouseMTf, were no
less viable than their MTfWT littermates. Furthermore, the MTfTg mice
did not exhibit any gross morphological or behavioural abnormalities
compared to MTfWT mice.
Breeding of mice heterozygous for MTf hyper-expression, resulted
in a distribution of 65%MTfTg and 35%MTfWT (Table 2). Again, this was
consistent with a normal Mendelian inheritance ratio of 75%
transgenic (50% heterozygotes and 25% homozygotes) to 25% MTfWT.
The expression of MTf in theMTfTgmice was clearly marked compared
to MTfWT animals (Fig. 1C and D).
3.5. Body weights and relative organ weights of MTfTg mice
The body weights of MTfTg and MTfWT mice were measured from
the ages of 3 to 7 weeks and are shown in Fig. 2A and B. When male
MTfTg mice were compared to male MTfWT control littermates, there
was no signiﬁcant difference in body weight (Fig. 2A). Similar data
demonstrating no difference in weight were obtained when examin-
ing female MTfTg mice compared to their female MTfWT littermates
(Fig. 2B). Organ to body weight ratios of 8 week old MTfTg and MTfWT
mice were also calculated. These data demonstrated no signiﬁcantMice were maintained on a basal rodent chow diet and watered ad libitum. The weights
e of three weeks. Over seven weeks, there were no signiﬁcant differences in total body
roup). Results are mean±SD. (C–D) Relative organ weights of eight week old male (C)
relative organ weight (as a percentage of total body weight) of the brain, heart, kidney,
sults are mean±standard error of the mean (SEM).
Table 3
Haematological and serum clinical chemistry indices in MTfTg mice compared to their MTfWT littermates at 8 weeks of age.
Indices Unit Male Female
MTfTg MTfWT MTfTg MTfWT
Haematological indicesa
Red blood cell (RBC) 1012/L 8.67±0.19⁎ 9.42±0.06⁎ 8.74±0.11⁎ 9.19±0.08⁎
White blood cell (WBC) 109/L 7.25±0.68 8.10±0.75 7.49±0.52 5.64±0.37
Hemoglobin (HGB) g/L 146±2 154±1 145±2 151±1
Hematocrit (HCT) % 47.6±1.1 51.3±0.5 47.5±0.7 49.6±0.4
Mean corpuscular volume (MCV) fL 54.8±0.1 54.4±0.2 54.3±0.2 53.9±0.1
Mean corpuscular hemoglobin (MCH) Pg 16.9±0.3 16.4±0.1 16.6±0.1 16.4±0.1
Mean corpuscular hemoglobin concentration (MCHC) % 30.9±0.6 30.0±0.2 30.6±0.2 30.5±0.1
Platelet (PLT) 109/L 794±43 724±40 551±63⁎ 826±18⁎
Clinical chemistry indicesb
Calcium mmol/L 2.56±0.03 2.58±0.04 2.63±0.02 2.67±0.02
Total protein g/L 52.7±0.7 52.0±0.9 54.3±0.6 56.3±1.0
Albumin g/L 29.5±0.4 29.1±0.5 32.6±0.4 33.9±0.6
Globulin g/L 23.2±0.3 22.8±0.5 21.7±0.4 22.3±0.5
Albumin/globulin ratio 1.27±0.04 1.28±0.05 1.51±0.05 1.52±0.06
Serum Fe μmol/L 21.1±1.3 21.5±0.8 27.1±1.2 27.5±0.4
Unsaturated iron-binding capacity (UIBC) μmol/L 35.4±1.2 33.3±0.9 29.7±1.4 31.3±1.2
Total iron-binding capacity (TIBC) μmol/L 56.5±0.3⁎ 54.9±0.6⁎ 56.8±1.0 58.8±1.4
Transferrin saturation % 37.3±7.1 39.3±4.5 47.8±6.9 46.8±2.3
Creatinine μmol/L 27.9±0.8⁎ 25.3±0.8⁎ 23.7±0.8 26.5±2.1
Serum urea nitrogen mmol/L 11.2±0.5 10.7±0.3 9.2±0.3 10.0±0.7
Glucose mmol/L 12.9±0.4 12.9±0.3 12.2±0.6 12.6±0.6
Triglyceride mmol/L 1.30±0.08 1.59±0.14 1.19±0.11 1.49±0.14
Amylase U/L 2898±123 4134±703 4735±1337 2996±380
Alkaline phosphatase (ALP) U/L 196±11 191±14 240±9 253±6
Alanine aminotransferase (ALT) U/L 69.7±16.0 56.5±4.6 44.5±6.4 53.7±11.6
Aspartate aminotransferase (AST) U/L 152±12 133±8 121±14 146±34
Results expressed as mean±SEM.
a n=8 for each genotype and sex.
b n=7 for each genotype and sex.
⁎ pb0.05 compared with MTfWT counterparts.
Table 4
Selectedmetal stores in the organs ofMTfTgmice compared to theirMTfWT littermates at
8 weeks of age.
Parameters Units Male Female
MTfTg MTfWT MTfTg MTfWT
Cu
Brain μg/g 10.9±0.5 11.4±0.2 12.6±0.5 12.2±0.2
Heart μg/g 17.2±0.3 17.1±0.3 17.0±0.4 17.1±0.2
Kidney μg/g 10.8±0.2 11.4±0.1 11.1±0.1 10.8±1.3
Liver μg/g 12.5±0.2 13.5±0.3 10.3±0.1 10.2±0.2
Spleen μg/g 1.1±0.3 3.7±1.6 1.6±0.3 0.5±0.1
Testis μg/g 3.5±0.2 2.8±0.2 – –
Fe
Brain μg/g 69±2 81±4 79±3 74±2
Heart μg/g 405±22 476±24 486±24 475±22
Kidney μg/g 218±6 235±5 280±9 263±27
Liver μg/g 180±7 184±7 273±10 272±10
Spleen μg/g 1120±127 1064±88 1790±163 2127±191
Testis μg/g 73±3 72±3 – –
Zn
Brain μg/g 60±2 73±4 72±3 66±1
Heart μg/g 66±1 67±1 68±1 68±1
Kidney μg/g 68±1 71±1 71±1 82±13
Liver μg/g 80±1 80±1 91±1 90±1
Spleen μg/g 88±2 89±2 91±3 86±3
Testis μg/g 107±5 109±4 – –
Results expressed as mean±SEM (n=8) for each genotype and sex.
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the MTfTg and MTfWT mice in either male nor female (Fig. 2C and D).
3.6. Haematological and biochemical parameters in the blood of
MTfTg mice
A panel of haematological indices (Table 3) was determined from
the MTfTg and MTfWT mice. A signiﬁcant decrease (pb0.05) was noted
in the erythrocyte (RBC) count of the MTfTg mice compared to the
MTfWT littermates in both males and females (Table 3). Additional
studies using mice 8–19 weeks old also showed a signiﬁcant (pb0.05)
reduction in the RBC counts (1012/L) in males (MTfTg=8.72±0.29,
MTfWT=9.72±0.06, n=15) and females (MTfTg=8.86±0.14,
MTfWT=9.38±0.10, n=14).
Moreover, the platelet (PLT) count was also signiﬁcantly decreased
(pb0.05) in femaleMTfTg animals (Table 3), but this was not observed
when comparing male MTfTg and MTfWT mice. Furthermore, no
signiﬁcant (pN0.05) alteration in platelet count was not observed in
another cohort of female animals at 8–19 weeks of age (MTfTg: 816±
140,MTfWT: 1079±150, n=14).
There were no signiﬁcant differences in all other haematological
indices when comparing MTfTg and MTfWT mice (Table 3). Additional
studies using the group of 29 mice (8–19 weeks old) described above,
also demonstrated no signiﬁcant alterations in these haematological
indices (data not shown). Selected clinical biochemistry parameters
(Table 3) were also assessed with no signiﬁcant differences being
detected between MTfTg and MTfWT littermates except for total iron-
binding capacity (TIBC) and creatinine levels (pb0.05) in male
animals. However, the signiﬁcant increase in these latter parameters
was not observed when comparing female MTfTg and MTfWT mice and
its relevance was uncertain. Furthermore, all of the haematological
and biochemical alterations described above were well within the
normal physiological limits described for C57/BL6J mice [48].3.7. Histopathological ﬁndings in tissue sections from MTfTg mice
Tissue specimens of brain, heart, kidney, liver, spleen and testis
were collected from MTfTg and MTfWT animals. Sections were stained
with either hematoxylin and eosin to detect morphological abnorm-
alities or Perls' stain for the presence of Fe(III) deposits. No
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animals were detected in any tissues (data not shown).
3.8. MTf hyper-expression does not affect normal Fe metabolism
MTf is a Tf homologue and shares many of its characteristics,
including the ability to speciﬁcally bind Fe [10,13]. To assess the effect
on MTf hyper-expression on Fe metabolism, serum and tissue Fe
indices were measured in 8 week old MTfTg and MTfWT littermates.
Male and female mice were assessed as separate groups due to the
known differences in Fe metabolism between the two sexes [49]. In
male and female mice, serum Fe levels, Tf saturation and tissue Fe
levels were not signiﬁcantly different (pN0.05) in MTfTg animals
compared with MTfWT littermates (Tables 3 and 4). Since MTf has an
Fe-binding site that is identical to Tf [3,10,12,14,15] which can bind
other transition metals [50], MTf may potentially bind other vital
metal ions such as Cu(II) and Zn(II). Hence, it was important to
examine the effects of the MTf hyper-expression on tissue Cu(II) and
Zn(II) levels. As found for Fe, no differences for Cu(II) nor Zn(II) were
observed (pN0.05) comparingMTfTgmicewith theirMTfWT littermates
(Table 4).
4. Discussion
Despite over twenty-ﬁve years of research following the initial
identiﬁcation of MTf as a Tf homologue [10], there is little evidence
regarding its precise molecular function(s) [14]. In this study, we
generated the ﬁrst transgenic mice that hyper-express MTf in a wide
variety of tissues to help elucidate its biological role(s). This is
important, as disease states (e.g., Alzheimer's disease and melanoma)
are associated with high MTf expression [3,11,13,26]. In the current
study, hyper-expression ofMTfmRNA inMTfTg mice was observed in a
wide variety of tissues and accompanied by a marked increase in MTf
mRNA and protein levels, demonstrating success of the lentiviral gene
delivery protocol.
Our data suggest that under normal laboratory housing conditions,
in a pathogen-reduced environment, MTfTg mice were born healthy
without overt abnormalities and were indistinguishable from their
MTfWT littermates. The MTfTg animals also displayed no alteration in
fecundity and there was no signiﬁcant decrease in the litter number/
size. In addition, a cohort of MTfTg mice has been kept for over
18 months with no abnormalities being detected (data not shown).
Despite evidence for the role of MTf in cellular proliferation and
migration in vitro [18,30],MTfTg mouse growth was essentially normal
in the presence of excess MTf expression. These observations may
indicate that MTf is only required at a certain threshold for its
physiological functions in vivo and that expression above this level
(such as in this transgenic) does not lead to any overt pathology.
The presence of a functional Fe-binding site in MTf [12,13,15],
suggested a potential role for MTf in Fe metabolism, particularly in
malignant melanoma cells that express high levels of this tumour
antigen [10]. Iron levels were also important to examine in MTfTg
mice, since there was increased Fe uptake from Fe-citrate by CHO
cells hyper-expressing MTf compared to wild-type cells [16].
However, our studies demonstrated that MTfTg mice demonstrated
no alterations in serum or tissue Fe levels in a variety of major
organs in comparison to MTfWT littermates. Hence, data from our
MTfTg animals suggested that hyper-expression of MTf in vivo does
not affect Fe metabolism. This agrees well with our previous studies
in vitro which demonstrated that MTf was not involved in Fe uptake
by melanoma cells with high MTf expression [14,20–22]. Moreover,
we generated a MTf−/− mouse which was viable and exhibited no
change in tissue and serum Fe levels or haematological indices
[18,19]. As noted from our previous investigations, loss of function of
molecules involved in Fe metabolism generally leads to dramatic
consequences, including lethality [47]. Hence, collectively these datain vitro and in vivo indicated that MTf has other functions distinct
from Fe uptake and metabolism.
It is of interest that there was a mild but signiﬁcant decrease of
erythrocyte number in both male and femaleMTfTg mice compared to
the MTfWT counterparts (Table 3). These data suggest that hyper-
expression of MTf has resulted in slight alterations of erythropoiesis
and/or erythrocyte turnover. Interestingly, a signiﬁcant change in
erythrocyte count was not observed in the MTf−/− mouse compared
to itsMTfWT littermates [18,19]. These data suggested that the effect on
erythrocyte number observed in MTfTg mice was due to MTf hyper-
expression. Since no changes were observed in serum or tissue Fe
levels in theMTfTg compared toMTfWT mice (Tables 3 and 4), the mild
changes in erythrocyte count were not linked to alterations in Fe
metabolism.
Considering the mechanism(s) responsible for the mild defect
leading to decreased erythrocyte number in the MTfTg mouse, it is of
interest that expression of avian MTf is restricted to a sub-population
of bone marrow cells (1% to 5%) thought to be eosinophil precursors
[5]. In fact, MTf has been suggested to be a stage-speciﬁc marker of the
eosinophil lineage [5]. However, no alteration in eosinophil numbers
in the peripheral blood of MTfTg compared to MTfWT mice was
identiﬁed in the current study (data not shown). Hence, the MTfTg
phenotypewas only slight, and further investigation into its molecular
nature is warranted in future studies. Themild decrease in erythrocyte
number in the MTfTg compared to MTfWT mice could be potentially
mediated by the increased turnover of these cells. However, there was
no detectable increase in splenic Fe levels in MTfTg mice relative to
theirMTfWT counterparts via Perls' staining or by direct determination
using ICP-AES (Table 4). We have previously shown in a variety of MTf
expressionmodels that therewere common changes in the expression
of genes involved in membrane transport, energy metabolism and cell
proliferation/survival [28]. Potentially, hyper-expression of MTf could
lead to alterations in expression of such genes that could directly or
indirectly lead to the mild haematological phenotype in the current
study.
In conclusion, this study is the ﬁrst to generate MTf hyper-
expressing transgenic mice to assess its biological function(s). The
MTfTg mice demonstrated that hyper-expression of MTf resulted in
viable animals with a mild haematological phenotype. Furthermore,
this study also conclusively demonstrated that MTf hyper-expression
does not alter Fe metabolism or homeostasis, but that its hyper-
expression slightly decreased erythrocyte number. Additional studies
are currently progressing to expose these animals to various stimuli to
uncover a potential phenotype.
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